SYROS PHARMACEUTICALS INC (SYRS)
US87184Q2066 - Common Stock
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
SYRS stock results show that Syros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Syros Pharmaceuticals (NASDAQ:SYRS) just reported results for the fourth quarte...
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Syros Pharmaceuticals Becomes Oversold (SYRS)
Syros to Participate in TD Cowen 44th Annual Health Care Conference
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
Is your portfolio is in dire need of making new all-time highs? A new economic cycle is to send these penny stocks with potential up.
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
Top Buys by Directors: Akkaraju's $4M Bet on SYRS
Syros Pharmaceuticals director buys sock worth $4M (NASDAQ:SYRS)
Syros Pharmaceuticals director buys $4M worth of shares, increasing total holding to 1.79M. Stock price up 2.6% in pre-market trading.
Syros Pharmaceuticals director buys stock worth $4M (NASDAQ:SYRS)
Syros Pharmaceuticals director buys $4M worth of shares, increasing total holding to 1.79M. Stock price up 2.6% in pre-market trading.
Syros prices capital raise of $45.0 million via securities offering (NASDAQ:SYRS)
Syros (SYRS) has priced an underwritten offering of 4.94 million shares of common stock at an offering price of $4.42 per share, and pre-funded warrants to purchase 5.24 million shares of..
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Syros stock jumps after data for leukemia drug (NASDAQ:SYRS)
Syros Pharmaceuticals (SYRS) stock soars 41% after positive early data from a Phase 2 trial for its oral leukemia drug tamibarotene in combination therapy. Read more here.
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing.
Syros to Participate in Upcoming Investor Conferences
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
Syros Pharmaceuticals announces job cuts, CEO change (NASDAQ:SYRS)
Syros Pharmaceuticals (SYRS) is cutting its workforce by 35%, appointing a new CEO, and seeing the departure of its chief scientific officer.